News | February 24, 2026
Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The therapy is currently completing Phase 1 clinical trials in renal cell carcinoma and non-small cell lung cancer
Hologic has been at the forefront of cervical cancer screening for decades
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
Subscribe To Our Newsletter & Stay Updated
